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Abstract
Background The role of complement in the atypical form of
hemolytic uremic syndrome (aHUS) has been investigated
extensively in recent years. As the HUS-associated bacteria
Shiga-toxin-producing Escherichia coli (STEC) can evade the
complement system, we hypothesized that complement dys-
regulation is also important in infection-induced HUS.
Methods Serological profiles (C3, FH, FI, AP activity, C3d,
C3bBbP, C3b/c, TCC, αFH) and genetic profiles (CFH, CFI,
CD46, CFB, C3) of the alternative complement pathway were
prospectively determined in the acute and convalescent phase
of disease in children newly diagnosed with STEC-HUS or
aHUS. Serological profiles were compared with those of 90
age-matched controls.
Results Thirty-seven patients were studied (26 STEC-HUS,
11 aHUS). In 39 % of them, including 28 % of STEC-HUS
patients, we identified a genetic and/or acquired complement
abnormality. In all patient groups, the levels of investigated
alternative pathway (AP) activation markers were elevated in
the acute phase and normalized in remission. The levels were
significantly higher in aHUS than in STEC-HUS patients.
Conclusions In both infection-induced HUS and aHUS pa-
tients, complement is activated in the acute phase of the dis-
ease but not during remission. The C3d/C3 ratio displayed the
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best discrepancy between acute and convalescent phase and
between STEC-HUS and aHUS and might therefore be used
as a biomarker in disease diagnosis and monitoring. The pres-
ence of aberrations in the alternative complement pathway in
STEC-HUS patients was remarkable, as well.
Keywords Atypical HUS . Complement . Hemolytic uremic
syndrome . STEC . Genetic aberrations . Children
Introduction
The hemolytic uremic syndrome (HUS) is a rare and severe
disease characterized by the triad of hemolytic anemia, throm-
bocytopenia, and acute renal failure. HUS is characterized
histologically by thrombotic microangiopathy (TMA): vascu-
lar abnormalities with glomerular endothelial damage, swell-
ing of the endothelium, endothelial detachment of the base-
ment membrane, intima fibrosis, and thrombosis [1]. In recent
years, knowledge of the pathogenesis of HUS has extended
tremendously [2]. In >90 % of cases, the disease is triggered
by an infection with Shiga-like toxin-producing Escherichia
coli (STEC-HUS). Non-STEC-HUS patients have a poor
prognosis, with high mortality and morbidity rates in the acute
phase and progression to end-stage renal disease (ESRD) in
50 % of cases. Several causes of this non-STEC-HUS have
been identified, including disorders of complement regulation
(aHUS) and various nonenteric infections, such as
Streptococcus pneumoniae (SP-HUS) [3].
Dysregulation of the alternative pathway (AP) of the com-
plement system plays an important role in the pathogenesis of
aHUS. Figure 1 presents a schematic overview of the alterna-
tive and terminal complement pathways. In recent years, DNA
mutation analysis of genes encoding complement proteins in
patients with aHUS have clearly demonstrated that in 50–
60 % of patients, mutations are found in CFH, CFI, CD46,
CFB, C3, and THBD [4–11]. A subgroup of patients with
aHUS has been described as having antibodies against the
C-terminus of FH (αFH) in combination with a polymorphic
homozygous deletion of the genes encoding complement-
factor-H-related proteins 1 and 3 (CFHR1/3) [12]. Aside from
the aforementioned genes, mutations have been identified in
two genes encoding coagulation proteins (DGKE and PLG)
[13, 14] and in cobalamin C (MMACHC) in combination with
complement aberrations [15].
Recent in vitro studies have shown that the microbial path-
ogens associated with HUS—or their toxins—can activate the
complement system and bind complement proteins. In this
way, the organism can protect itself against complement acti-
vation [16–18]. Based on the similarity of the clinical mani-
festations of complement-mediated and infection-induced
HUS and the knowledge that bacteria can use complement
regulators to survive in the host, we hypothesized that also
in patients with STEC-HUS, a dysregulation of the comple-
ment system has an important place in the pathogenesis.
Anecdotal reports have shown low C3 levels and in-
creased complement activation products in children with
STEC-HUS, but usually only a few activation markers
were measured and in a small research population
[19–23]. To answer the question of whether alterations
in the alternative complement pathway are common in
patients with all forms of HUS, we prospectively deter-
mined genetic and serological complement profiles in se-
rum and plasma of children with STEC-HUS or aHUS in
the acute and convalescent phase of the disease.
Currently, in most studies, control ranges for adults are
used to interpret results of serological complement tests
in children, which is an important shortcoming in the
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Fig. 1 Alternative and terminal pathway of the complement system. The
central complement component C3 is spontaneously activated at a very
low rate to C3b, thereby generating the C3 breakdown products C3d and
C3b/c. C3b is able to attach to the surfaces of pathogens and host cells.
There it binds complement factor B (FB), which is proteolytically
activated by factor D (FD). The resulting C3bBb complex is stabilized
by properdin (FP), and this C3 convertase can cleave and activate more
C3 molecules. This activation leads to amplification of the complement
cascade via the C5 convertase, to the formation of the membrane attack
complex (C5b-9 or TCC), and, eventually, to cell lysis. The regulators of
the complement system, important in the protection of host cells against
complement activation, and the complement-inhibiting therapeutic
eculizumab, are depicted at the level of action
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correct interpretation of the results. Therefore, following a
strict protocol, we screened complement profiles in age-
matched, healthy Dutch infants and children to obtain
reliable reference intervals by which to interpret our stud-
ies in HUS children.
Methods
Patients and controls
Newly diagnosed children (0–18 years) with STEC-HUS or
aHUS referred to the pediatric nephrologyward of all academ-
ic hospitals in The Netherlands between August 2010 and
September 2013 were el igible for enrolment . In
The Netherlands, the policy is to refer every suspected HUS
patients to the academic setting. We expect that only a very
low proportion (approximately 5–10 %) of STEC-HUS pa-
tients were not referred and would not have been assessed in
this study. HUS was diagnosed based on the triad of microan-
giopathic hemolytic anemia, thrombocytopenia, and acute re-
nal failure; patients were further classified as STEC-HUS, SP-
HUS, or aHUS, as previously described [24]. STEC-HUS
cases were confirmed by stool samples [culture and/or stx1
and stx2 detection by polymerase chain reaction/enzyme im-
munoassay (PCR/EIA)].
Ethylenediaminetetraacetic acid (EDTA) plasma and/or se-
rum samples were collected before the initiation of therapy
[acute-phase sample; usually 3–7 days after onset of gastroin-
testinal (GI) complaints] and 14–28 days later (convalescent
phase sample), preferably when all signs of TMA had disap-
peared. To obtain a reliable control population, 90 pediatric
individuals of different ages were enrolled in the study to
assess the correlation between complement system and age.
Exclusion criteria were fever (>38.5 °C), signs or symptoms
of infection (bacterial or viral), chronic illness, immune-
suppressive medication, acquired or congenital immune defi-
ciencies, age <2 days of life, intensive ventilation, and surgical
interventions in last 3 days.
Sample collection
For serological complement profiling, EDTA blood sam-
ples were placed on ice immediately after collection and
were processed within 1 h (10 min, 2500 g, 4 °C);
whole-blood samples were allowed to coagulate for 45–
60 min before processing (10 min, 2500 g, 4 °C). Serum
and EDTA plasma samples were stored at −80 °C in
aliquots.
For DNA analysis, genomic DNA was isolated from pe-
ripheral blood leukocytes according to established protocols.
For one STEC-HUS patient, no material was available for
genomic DNA isolation.
Genetic analysis
Genomic DNA was amplified for CFH [National Centre for
Biotechnology Information (NCBI) RefSeq NM_000186.3],
CFI (NM_000204.3), CD46 (NM_002389.4), C3
(NM_000064.2), and CFB (NM_001710.5) by means of
PCR, as previously described [8]. Primer data are available
upon request. Nonsynonymous aberrations were checked in
the literature, evolutionairy conservation (USCS Genome
Browser; http://genome.ucsc.edu), in silico prediction
programs [Sorting Intolerant From Tolerant (SIFT);
http://sift.jcvi.org/; a <0.05 was considered not tolerated],
and PolyPhen-2 (Polymorphism Phenotyping v2;
http://genetics.bwh.harvard.edu/pph2/). We also searched in
the Exome Variant Server (http://evs.gs.washington.
edu/EVS/), the Exome Aggregation Consortium (ExAC,
http://exac.broadinstitute.org/), and in an in-house database,
which all contain results of whole-exome sequencing of
>5000 individuals of European background (non-Finnish for
the ExAC database).
Presence of autoantibodies against factor H and anti-O157
LPS antibodies
Acute-phase serum samples were tested for the presence of
αFH and anti-O157 lipopolysaccharide (LPS) by means of
enzyme-linked immunosorbent assay (ELISA), as described
previously [25, 26]. LPS from E. coli O157:H7 for coating
was obtained via List Biological Laboratories (Campbell, CA,
USA).
Serological complement profiling of the alternative
complement pathway
The C3 concentration was determined by nephelometry
(BN™ II System, Siemens Healthcare Diagnostics,
Erlangen, Germany) using reagents from Beckman Coulter
Inc (Brae, CA, USA); levels were standardized against the
ERM‐DA470k/IFCC serum [27]. Levels of FH and FI were
determined by radial immunodiffusion. For FH, a rabbit anti-
serum raised against purified human factor H was used.
Calibration was based on serial dilutions of normal human
serum with a known concentration of FH (in mg/L). For FI,
a goat antiserum raised against purified human factor I was
used. Calibration was based on serial dilutions of normal hu-
man serum and expressed as percentage of the value in this
standard human serum (% NHS). To analyze AP activity, a
commercially available ELISA kit for total functional assess-
ment of the AP was used according to the manufacturer’s
protocol (Euro Diagnostica, Malmö, Sweden).
Levels of the C3 degradation products C3d and C3b/c
and the AP convertase C3bBbP were quantified in EDTA
plasma using ELISA, as previously described in detail
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[28, 29]. As the initial C3 concentration may influence
the C3d level, the C3d/C3 ratio was calculated as an
extra marker of AP activation independent of the concen-
trations of individual molecules. For this matter, C3d
levels were multiplied by 100 and divided by C3 levels.
The fluid-phase terminal complement complex (TCC)
was measured using a commercially available ELISA
kit (Hycult Biotech, Uden, The Netherlands), according
to the manufacturer’s protocol.
Statistical analysis
A linear regression analysis was performed for the con-
trol group to investigate the possible correlation between
age and complement profiles. For each investigation, a
D’Agostino-Pearson normality test was executed to
assess whether the controls were sampled from a
Gaussian distribution. When controls were normally dis-
tributed, a one-way analysis of variance (ANOVA) with
a Dunnett’s post test was executed to analyze differences
between controls and independent patient groups; in case
controls did not pass the normality test, a one-way
ANOVA with a Dunns’ post-test was performed. A
Mann–Whitney test was used to investigate the differ-
ence in age between STEC-HUS and aHUS patients
and to compare between the acute and convalescent
phase in these independent patient groups. To compare
C3d/C3 ratios between patient groups in the acute phase
of disease, a Pearson’s chi-square test was performed. All
statistical analyses were performed using GraphPad
PRISM software (version 5.03 for Windows, GraphPad
Software), except for the Pearson’s chi-square test, which
was executed in SPSS (version 20, IBM).
Results
Clinical characteristics of included patients
Thirty-seven patients, all with a Caucasian background,
were enrolled in this study between 2010 and 2013: 26
STEC -HUS pa t i e n t s a n d 11 aHUS pa t i e n t s .
Epidemiological features, genetic results, and clinical
characteristics (presenting symptoms, treatment, and out-
come) for 35 patients (94.6 %) are listed in Table 1. The
clinical courses of two patients (P1 and P6) have been
extensively described [30, 31]. Mean age of all patients
at presentation was 6.6 years (6.6 years for STEC-HUS;
6.5 years for aHUS). No significant difference was seen
in age at presentation between STEC-HUS and aHUS
patients (P = 0.9875; Fig. 2). Even though in the litera-
ture it is stated that STEC-HUS is usually diagnosed in
children between 2 and 5 years of age, in our study, half
of the STEC-HUS patients (13/26; 50.0 %) were >5 years
of age (range 0.4–17.8 years).
Moe than 60 % of the STEC-HUS cases (16/26) were
preceded by a proven infection with STEC O157. In four
patients (15.4 %), culture and/or PCR was positive for
STEC-infection, but no serotype could be identified;
these patients were all negative for anti-O157 LPS anti-
bodies. The remaining cases were infected with STEC
O26, O5, or O104. All STEC-HUS patients presented
with (bloody) diarrhea and/or gastrointestinal complaints;
one patient also had an upper respiratory tract infection.
Neurological complications were seen in seven STEC-
HUS patients (7/23; 30.4 %). Two of these patients had
other extrarenal complications as well: one had chronic
venous insufficiency during the HUS episode, and the
other was diagnosed with sigmoid stenosis due to HUS
3 months after discharge, for which a sigmoid resection
and end-to-end anastomosis was needed [30]. Dialysis
was needed in 65.2 % (15/23) of the STEC-HUS patients
(average duration 16 days); the other patients recovered
without the need for renal replacement therapy. Two
STEC-HUS patient were treated with plasmapheresis
subsequent to dialysis. In one of them, plasmapheresis
was indicated because of anuria, symptoms of ileus,
and severity of neurological condition; plasma therapy
was stopped when an STEC O26 infection was con-
firmed. Two STEC-HUS patients were treated with
eculizumab: one STEC O104 patient was treated for
8 weeks in the ad hoc, off-label trial during the
German outbreak; the other had such an unusual presen-
tation (12 years old, upper respiratory tract infection, no
bloody diarrhea) that aHUS was suspected and one dose
of eculizumab was given before anti-O157 LPS antibod-
ies were identified. The majority of STEC-HUS patients
had a good outcome with normal renal function, al-
though hypertension and/or proteinuria were still present
after >1 year following the acute phase in eight patients
(8/23; 34.8 %).
Interestingly, 70 % of aHUS patients presented with
GI complaints: 18 % with diarrhea and 54 % with other
GI symptoms, such as stomach aches and vomiting. No
bloody diarrhea was seen in aHUS patients. No
extrarenal complications were seen in these patients,
and the majority were treated with both dialysis (average
duration 9 days) and plasma therapy (average number of
sessions 14) to control renal failure. Sequelae were still
present in 70 % of aHUS patients, in most cases both
hypertension and proteinuria. For three aHUS patients,
the HUS episode at the time of the study was a recur-
rence. In one of these patients (P20), the first episode
was thought to be induced by an STEC infection based
on presentation with bloody diarrhea. One aHUS patient
(P24) was enrolled in the pediatric eculizumab trial [32],
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and a third, with a recurrence, was treated with
eculizumab outside the pediatric trial. Eculizumab treat-
ment had to be discontinued in both patients when the
trial ended, after which a relapse of disease occurred.
These patients are now on maintenance treatment with
eculizumab.
Genetic and/or acquired complement aberrations in HUS
patients
All but one patient in the study were screened for mutations in
the complement genes CFH, CFI, CD46, CFB, and C3, all of
which are associated with aHUS, and for the presence ofαFH.
Table 1 Epidemiological and
clinical features of studied
patients
Feature All patients STEC-HUS aHUS
Number 37 26 (68.4 %) 11 (28.9 %)
Gender 20 M : 17 F 13 M : 13 F 7 M : 4 F
Age (years) mean ± SD (range) 6.6 ± 4.8 (0.4–17.8) 6.6 ± 5.3 (0.4–17.8) 6.5 ± 3.8 (0.5–12.6)
Follow-up (years) mean ± SD (range) 2.9 ± 0.9 (1.3–4.4) 2.7 ± 0.9 (1.3–4.4) 3.1 ± 1.0 (1.9–4.3)
Serotype Not applicable O157: 16 (61.5 %) Not applicable
O26: 4 (15.4 %)
O5: 1 (3.8 %)
O104: 1 (3.8 %)
Not serotyped, but
α-O157 negative:
4 (15.4 %)
Presentation
Diarrhea 14 (34) 12 (23) 2 (11)
Bloody diarrhea 9 (34) 9 (23) 0 (11)
Gastrointestinal symptoms without diarrhea 8 (34) 2 (23) 6 (11)
Upper respiratory tract infection 4 (34) 1 (23) 3 (11)
Oligo/anuria 14 (34) 8 (23) 6 (11)
Headache 1 (34) 0 (23) 1 (11)
Extrarenal complications
None 27 (34) 16 (23) 11 (11)
Yes 7 (34) 7 (23) 0 (11)
Neurological 7 (34) 7 (23) 0 (11)
Intestinal (sigmoid stenosis, peritonitis) 1 (34) 1 (23) 0 (11)
Chronic venous insufficiency thrombosis 1 (34) 1 (23) 0 (11)
Treatment
Spontaneous remission 9 (34) 8 (23) 1 (11)
Dialysis 13 (34) 13 (23) 0 (11)
Plasma therapy 3 (34) 0 (23) 3 (11)
Dialysis and plasma therapy 9 (34) 2 (23) 7 (11)
Eculizumab 5 (34) 2 (23) 3 (11)
Outcome
Normal renal function 26 (33) 18 (23) 8 (10)
Hypertension1 and proteinuria2 8 (33) 3 (23) 5 (10)
Hypertension1 2 (33) 1 (23) 1 (10)
Proteinuria2 4 (33) 4 (23) 0 (10)
Maintenance treatment with eculizumab 2 (33) 0 (23) 2 (10)
Relapses after this episode 3 (33) 0 (23) 3 (10)
Genetic or acquired complement aberrations
(see Table 2)
Total 14/36 (38.9 %) 7/25 (28.0 %) 7/11 (63.3 %)
CFH 2/36 (5.6 %) 2/25 (8.0 %) –
CD46 2/36 (5.6 %) – 2/11 (18.2 %)
C3 3/36 (8.3 %) 2/25 (8.0 %) 1/11 (9.1 %)
C3 and αFH 1/36 (2.8 %) – 1/11 (9.1 %)
αFH 6/36 (16.7 %) 3/25 (12.0 %) 3/11 (27.3 %)
For clinical features, the numbers of patients with data available are reported in parentheses
αFH autoantibodies against factor H, aHUS atypical HUS, C3 complement component 3, CD46 membrane
cofactor protein, CFH complement factor H, HUS hemolytic uremic syndrome, SD standard deviation, STEC-
HUS Shiga-toxin producing Escherichia coli-induced HUS
1Hypertension: a systolic and/ or diastolic pressure ≥ 2.0 standard deviation scores compared with normal values
for age, gender, and height
2 Proteinuria: > 2 years old > 0.2 mg/mg (>22.6 mg/ mmol or 0.226 g/10 mmol); < 2 years old > 0.5 mg/mg
(>56.6 mg/mmol or 0.566 g/10 mmol)
Pediatr Nephrol
In 38.9 % (14/36) of the patients, including 7/25 STEC-HUS
patients, we identified a genetic and/or acquired complement
abnormality. Characteristics of the identified mutations are
depicted in Table 2.
Correlation between serological complement profiles
and age in healthy children
We included 90 control patients (179 days to 18 years old) to
define the correlation between complement levels/activity and
age. The individual profiles for controls and those of patients in
the acute phase of disease are shown in Fig. 3. No correlation
was seen in healthy children between age and serological com-
plement profiles except for C3d levels, which slightly decreased
with increasing age (P = 0.0017; R2 = 0.1086). All levels were
within adult reference ranges, although FI levels for pediatric
controls are around the lower limit of the adult reference inter-
val. For comparison of complement profiles between healthy
children and patients, results of pediatric controls were grouped.
Serological complement profiles in STEC-HUS, aHUS,
and SP-HUS patients
Levels of individual complement proteins C3, FH, and FI; AP
activity, and the activation products C3d, C3bBbP, C3b/c, and
TCC were measured in serum and EDTA plasma of HUS
patients on admission and 14–28 days later. Results were com-
pared with those of healthy pediatric controls (Fig. 3 and
Electronic Supplementary Resource 1). In the acute phase,
patients had slightly decreased complement C3 levels com-
pared with pediatric age-matched controls, although the alter-
ations were not significantly different between groups
(Fig. 4a). These levels increased in remission in both STEC-
HUS and aHUS patients. Levels of FH in STEC-HUS patients
STEC-
HUS
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were significantly elevated compared with controls (P < 0.001
for the acute phase and P < 0.01 for the convalescent phase;
data not shown); for FI levels, this was the case for all patient
groups (P < 0.001; data not shown).
The mean AP activity in both phases was higher in patients
than in controls, but this was not significantly different in all
patient groups (Fig. 4d). Individual AP activity, however, was
comparable with respective age-matched controls (Fig. 3d). In
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Fig. 3 Serological complement profiles in individual controls and patients
with Shiga-toxin-procuding Escherichia coli-induced hemlytic uremic syn-
drome (STEC-HUS) and atypical HUS (aHUS) in the acute phase of disease.
Serum or plasma samples of 90 controls (aged 4 months to 18 years) and of
HUS patients in the acute phase were analyzed for levels of alternative path-
way (AP) proteins C3 (a), AP activity (b), and complement activation
markers C3d, theC3d/C3 ratio, C3bBbP,C3b/c, andTCC (c–g). Each symbol
indicates an individual control or patient; controls are symbolized with black
dots, STEC-HUS patients with red triangles, and aHUS patients with green
triangles. Control ranges of adult individuals for C3 (700–1500 mg/l), AP
activity (30–113 %), C3d (<3.3 %), and TCC (<5 AU) levels are shown in
grey. No adult reference ranges are available for the C3d/C3 ratio, C3bBbP,
and C3b/c, but the reference interval as defined in our study (mean + two
standard deviations of pediatric control values), is depicted in grey.TCC ter-
minal complement component
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the acute phase, the levels of AP activation markers C3d
(P < 0.001 for STEC-HUS and aHUS), C3bBbP (STEC-HUS:
P < 0.01; aHUS: P < 0.001), and C3b/c (STEC-HUS: n.s.;
aHUS: P < 0.01) were increased as well, as depicted in Fig. 4e,
g, and h. The terminal AP marker TCC was only significantly
increased in STEC-HUS patients (P < 0.01; Fig. 4i); TCC levels
in aHUS and SP-HUS patients, however, were above the mean
of pediatric controls as well, although not significantly. In all
patient groups, levels of complement activation markers normal-
ized to about control levels in the convalescent phase.
As C3d levels were age dependent, we calculated the C3d/
C3 ratio as an extra marker of AP activation independent of
initial C3 levels (Figs. 3f and 4f). This ratio showed no age-
dependent effect. In the acute phase, the mean ratio in patients
was more than three times higher than in controls (20.00 vs.
5.86; P = 0.0003). No significant difference was found be-
tween STEC-HUS and aHUS patients, but at a more detailed
inspection of individual ratios, two thirds of aHUS patients
had a C3d/C3 ratio >2.75, while 88 % of STEC-HUS patients
had a ratio C<2.75 (P = 0.021). The other AP activation
markers displayed a significant difference between STEC-
HUS and aHUS patients in the acute phase of disease as well
(C3bBbP: P = 0.011; C3b/c: P = 0.027).
The presence of a genetic aberration or αFH could not be
linked to an altered serological complement profile: not all
patients with a complement aberration displayed complement
activation for the analyzed biomarkers in the acute and/or
convalescent phase (Electronic Supplementary Resource 1).
However, the power of this analysis was hampered bymissing
samples for analysis.
Discussion
To investigate the role of the alternative complement pathway
in HUS in general (infection-induced and aHUS), samples of
37 children with HUS of any etiology were collected in both
the acute and convalescent phases of the disease. Levels of
individual complement proteins and complement activation
markers were measured. It was demonstrated that in the acute
phase of the disease, both infection-induced and aHUS pa-
tients trended toward decreased average C3 levels and
increased average AP activity, even though this difference
was not statistically significant in all groups. Complement
activation products C3bBbP and C3d and the C3d/C3 ratio
were all significantly increased in STEC-HUS and aHUS pa-
tients. In aHUS patients, C3b/c was increased as well. This
complement activation normalized to control levels in remis-
sion, except for C3bBbP in STEC-HUS patients. Our results
corroborate previous reports of complement activation in chil-
dren with STEC-HUS [19–23].
Thurman et al. [21] mention that measurement of TCC
might be useful in monitoring the course of the STEC-HUS,
and recent studies have shown that the activation products
C3bBbP, C3b/c, and TCC can be used as biomarkers for dis-
ease activity in aHUS patients [33]. In our study, similar re-
sults were obtained in aHUS patients for C3bBbP and C3b/c,
which all normalized in the convalescent phase, but not for
TCC, levels of which levels did not change compared with the
acute phase. Volokhina et al. used remission samples of pa-
tients who had their last aHUS episode more than 1 year pre-
viously, while our samples were collectedwithin 1month after
the disappearance of clinical HUS symptoms. It seems that in
aHUS, the terminal pathway remains activated for a longer
period than the AP. No significant difference was seen be-
tween acute and convalescent C3bBbP and C3b/c levels in
STEC-HUS patients.
In both patient groups, the C3d/C3 ratio gives the clearest
difference between the acute and convalescent phases of dis-
ease in all patient groups (P < 0.01 STEC-HUS, P < 0.001
aHUS) and the C3d/C3 ratio may therefore be the most prom-
ising biomarker with which to monitor disease activity. The
finding of increased complement activation products in the
circulation during the acute phase of aHUS indicates that in
this patient group, the AP might not only be dysregulated at
the level of the glomerular endothelium, as was suggested in a
recent study [34]. Noris et al. only measured activation prod-
ucts of the terminal pathway (TCC and C5a), but Volokhina
et al. [33] and our study also investigated activation products
of the AP. Our results with altered levels of C3bBbP, C3b/c,
and the C3d/C3 ratio, but not TCC, show that increased com-
plement turnover occurs, at least at the C3 level.
Based on clinical presentation, it sometimes can be
difficult to distinguish between STEC-HUS and aHUS
patients: no age differences were seen, many STEC-
HUS cases were >5 years, and the majority of aHUS
patients presented with gastrointestinal problems and/or
diarrhea, which has been described before [35, 36].
Furthermore, not all STEC-HUS patients had (bloody)
diarrhea, which again clearly shows that postdiarrheal
onset does not exclude the possibility of aHUS or that
the absence of diarrhea excludes STEC-HUS. The C3d/
C3 ratio at admission was on average twice as high in
aHUS patients than in infection-induced HUS patients;
this was not a statistically significant difference, and
Fig. 4 Serological levels of complement C3, alternative pathway
activation, and levels of complement activation products in patients
with Shiga-toxin producing Escherichia coli-induced hemolytic uremic
syndrome (STEC-HUS) and atypical HUS (aHUS) in the acute and
convalescent phases of disease. Serum or plasma samples taken in both
phases were analyzed for the complement proteins C3 (a), for alternative
pathway activation (b), and for the levels of C3d, C3d/C3 ratio, C3bBbP,
C3b/c, and TCC (c–g). The number of screened patients is indicated
within parentheses. * P < 0.05; **P < 0.01; ***P < 0.001. Bars mean;
error bars standard error of mean. AP alternative pathway, conv conva-
lescent, TCC terminal complement component
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was most probably due to the low number of patients.
Based on visual analysis of the data plot, aHUS patients
were more likely to have a C3d/C3 ratio >2.75 compared
with STEC-HUS (66.7 vs. 11.8 %; P = 0.021). Levels of
C3bBbP and C3b/c were also significantly higher in
aHUS than in STEC-HUS patients. Based on our results,
the investigated AP activation products may therefore be
used as biomarkers to discriminate at admission between
STEC-HUS and aHUS. As C3d is a more commonly
performed measurement than C3bBbP and C3b/c, the
C3d/C3 ratio is preferred, and this ratio may be used to
monitor disease activity as well. The calculated ratio also
compensates for the observed C3 consumption occurring
in aHUS patients compared with controls. As the number
of patients in the current study was very small, a pro-
spective study is needed to determine sensitivity and
specificity before these assays are implemented in rou-
tine diagnostics in case of HUS suspicion.
As the human complement system is one of first parts of
innate immunity to be activated whenmicro-organisms invade
the body, at this moment, we cannot exclude that the observed
AP activation in STEC-HUS is only an infection-related phe-
nomenon—for example, due to endotoxins or other proteins
produced by the bacteria. In meningococcal infection, for in-
stance, C3 activation and TCC are both increased, with a
strong correlation between complement activation and levels
of endotoxins produced byNeisseria meningitidis [37]. As the
classic and lectin pathway could be activated as well due to the
infection, we studied the classic pathway in both the acute and
convalescent phase (data not shown). Even though activity
was slightly increased in all patient groups, no difference
was seen between disease phases or between STEC-HUS
and aHUS patients (data not shown). The lectin pathway
was not investigated.
It is already known that STEC is able to manipulate com-
plement factors in multiple ways: for instance, binding of
Shiga toxin to FH results in a delayed cofactor activity on
the cell surface, but this is not so in the fluid phase [16]; the
autotransporter EspPwas shown to cleave C3/C3b and C5 and
decrease complement activation in serum [38]. We were sur-
prised to see that in almost 30 % of STEC-HUS patients, a
genetic complement aberration could be identified. Several
case reports of STEC-HUS patients with complement muta-
tions have been published [35, 39–42], but so far, only one
larger cohort was investigated; in 3/25 (12.0 %) STEC-HUS
patients, a mutation was identified [23].
In needs to be mentioned that the genetic aberrations
identified in STEC-HUS patients are all variants of un-
known significance. Most of the identified genetic vari-
ations have been described before as risk factors for oth-
er diseases associated with a dysregulated complement
system (aHUS and/or age-related macular degeneration),
and functional studies showed that these aberrations
either influence the binding capacity of a complement
to C3b regulators or affect the inactivation of C3 [5,
8–10, 43–45]. However, these were all reported in a
(very) low frequency in the general population, and pre-
diction software was not conclusive about their pathoge-
nicity, which makes it more likely that these variants are
disease modifying and not disease causing. This is not
remarkable, as an incomplete penetrance is seen in HUS:
healthy family members can carry disease-causing muta-
tions [46]. This indicates that additional triggers, genetic
and/or environmental, are probably needed for the dis-
ease to develop. It would be of great value to compare
the level of complement aberrations in patients who de-
velop HUS in a STEC outbreak to those that do not
develop HUS, and see whether these numbers can be
confirmed. A much larger study is warranted to deter-
mine the relevance of genetic variants in STEC-
mediated HUS.
As in other studies, we could not link an altered comple-
ment profile in either the acute or convalescent phase of the
disease to the presence of a genetic or acquired complement
aberration (mutation or αFH; Electronic Supplementary
Resource 1) [34]. Patients both with and without identified
mutations displayed similar complement abnormalities re-
garding protein level, and not all patients with a complement
aberration demonstrated complement activation for the ana-
lyzed biomarkers in the acute phase and/or in remission.
These findings might also indicate that additional, as yet un-
discovered, complement aberrations might play a role in some
HUS patients with an abnormal serological complement pro-
file. Moreover, abnormalities in complement regulation may
only occur at the level of the endothelial cell surface and not
systemically [34]. Therefore, serological levels of individual
proteins may be normal in patients with complement dysreg-
ulation and thus cannot exclude a genetic complement disor-
der. The method used to monitor C3 and C5b–9 deposition on
unstimulated human microvascular endothelial cells [34],
however, is labor intensive and technically complex and can
certainly not be performed in every clinic.
The finding of mutations and αFH in STEC patients
argues that there might be undiagnosed cases of aHUS
triggered by a STEC infection on a genetic background
of impaired complement regulation, and that these might
influence the development of disease after infection (only
5–15 % of infected individuals develop STEC-HUS).
Unlike aHUS patients, so far, the investigated infection-
induced HUS patients of our study with complement
mutations or αFH had a good outcome and no recur-
rences. These patients, however, might be prone to de-
velop recurrence. Indeed, one aHUS patient (P20) had a
previous episode of HUS preceded by bloody diarrhea,
but the recurrent episode had no evidence of a preceding
STEC infection. In this patient, a CD46 mutation was
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identified (Table 2). The same occurred in two Italian
patients: they were first diagnosed with STEC-HUS, but
after HUS recurrence, a complement mutation was iden-
tified [35]. Systematic follow-up of STEC-HUS patients,
including genetic screening, is needed to learn more
about the role of complement aberrations in STEC-HUS
and to determine whether patients with STEC-HUS with
mutations or αFH need to be grouped as aHUS patients
instead.
Use of the complement inhibitor eculizumab in STEC-
HUS is still questionable. Even though individual patients
can respond rapidly with efficient recovery, in larger cohorts
of STEC-HUS patients, no significant differences have been
seen on mortality or morbidity with the use of eculizumab
[47–50].
All together, we conclude that in both infection-induced
HUS and aHUS patients the complement system is activated
in the fluid phase during the acute phase of disease but not
during remission. Measuring AP activation products, in par-
ticular C3d/C3 ratio, might help in monitoring disease activity
and distinguishing between the different HUS etiologies. The
exact role of altered complement activation in the pathogene-
sis of STEC-HUS, however, has not been fully elucidated.
Interestingly, genetic and/or acquired complement aberrations
(mutations and/or autoantibodies) were not only identified in
aHUS patients but also in 30 % of infection-induced HUS
patients. This indicates that genetic screening might be ad-
vised in these patients as well, as the presence of a genetic
defect could influence the recurrence risk.
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